SXTP
60 DEGREES PHARMACEUTICALS, INC.
$1.43
+0.70%
$3.8M
No data for this timeframe.
Vol
Market Cap$3.8M
Cap SizeNano Cap
Analyst ConsensusStrong Buy (75%)
Reddit Sentiment60° Warm
SEC Reports1
Press Releases3
Recent Activity
May 26, 2026
Press
60 Degrees Pharmaceuticals announced enrollment of the first patient of the 2026 tick season in a Phase 2 clinical trial
Impact 4/10
May 26, 2026
fda
60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis
60 Degrees Pharma enrolls first 2026 babesiosis trial patient ahead of schedule, supporting possible
May 15, 2026
SEC
Sixty Degrees Pharmaceuticals reported Q1 2026 revenue of $162K (down ~1% YoY) and a net loss of $1.28 per share, signif
PRESS-RELEASE — Impact 6/10
Mar 31, 2026
Press
Sixty Degrees Pharmaceuticals reported FY2025 net product revenue growth of 65% to $1.005 million, driven by higher sale
Impact 5/10
Price Targets
$3.70
+166.2% upside
Strong Buy
Current $1.39
Low $3.70
Median $3.70
High $3.70
1 analysts
$3.70
$3.70
Analyst Ratings
2Strong Buy
4Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 22, 2026 | Ascendiant Capital | MAINTAIN | Buy → Buy |
| May 20, 2026 | HC Wainwright & Co. | DOWNGRADE | Buy → Neutral |
| Apr 9, 2026 | Ascendiant Capital | MAINTAIN | Buy → Buy |
| Jan 27, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.89 ▼ -14.1% | $-0.89 — $-0.89 | 79% YoY | 1 |
| Next Q | $-0.85 ▼ -7.6% | $-0.85 — $-0.85 | 66% YoY | 1 |
| Current FY | $-3.45 ▼ -8.5% | $-3.45 — $-3.45 | 69% YoY | 1 |
| Next FY | $-3.58 | $-3.58 — $-3.58 | -4% YoY | 1 |
Latest Reports
NEUTRAL
Press
4/10
60 Degrees Pharmaceuticals announced enrollment of the first patient of the 2026 tick season in a Phase 2 clinical trial
May 26, 2026
BEARISH
PRESS-RELEASE
6/10
Sixty Degrees Pharmaceuticals reported Q1 2026 revenue of $162K (down ~1% YoY) and a net loss of $1.28 per share, signif
May 15, 2026
Reddit Sentiment
60°
Warm
Bearish
Neutral
Bullish
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
1 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 0 neutral. Avg impact: 6.0/10.
NEUTRAL
4/10
60 Degrees Pharmaceuticals announced enrollment of the first patient of the 2026 tick season in a Ph
May 26, 2026
MIXED
5/10
Sixty Degrees Pharmaceuticals reported FY2025 net product revenue growth of 65% to $1.005 million, d
Mar 31, 2026
NEUTRAL
4/10
Sixty Degrees Pharmaceuticals submitted a New Dietary Ingredient Notification (NDIN) to the FDA for
Mar 18, 2026
Current analyst consensus: Buy (75% buy). Based on 8 analysts: 2 strong buy, 4 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$3.70 mean target
+166.2% upside
Strong Buy (3.00)
$3.70 Low
$3.70 High
| Metric | Value |
|---|---|
| Current Price | $1.39 |
| Target Low | $3.70 |
| Target Mean | $3.70 |
| Target Median | $3.70 |
| Target High | $3.70 |
| # Analysts | 1 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.89 | $-0.89 | $-0.89 | 79.4% | -14.1% | 0↑ 1↓ | $0.0B | -39.9% | 1 |
| Next Q 2026-09-30 |
$-0.85 | $-0.85 | $-0.85 | 66.4% | -7.6% | 0↑ 1↓ | $0.0B | -49.9% | 1 |
| Current FY 2026-12-31 |
$-3.45 | $-3.45 | $-3.45 | 69.0% | -8.5% | 0↑ 1↓ | $0.0B | -10.5% | 1 |
| Next FY 2027-12-31 |
$-3.58 | $-3.58 | $-3.58 | -3.8% | — | — | $0.0B | 77.8% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.890 | |
| 7d ago | $-0.780 | -0.110 |
| 30d ago | $-0.780 | -0.110 |
| 60d ago | $-1.960 | +1.070 |
| 90d ago | $-1.960 | +1.070 |
2 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 22, 2026 | Ascendiant Capital | MAINTAIN | Buy | Buy |
| May 20, 2026 | HC Wainwright & Co. | DOWNGRADE | Buy | Neutral |
| Apr 9, 2026 | Ascendiant Capital | MAINTAIN | Buy | Buy |
| Jan 27, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 4 | 2 | 0 | 0 | 75% | |
| May 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Apr 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Mar 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Feb 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Jan 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
60°
Warm
Bearish
Neutral
Bullish
1 mentions
1 bullish
0 bearish
1 time period
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Jan 26, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
May 26, 2026
fda
60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis
60 Degrees Pharma enrolls first 2026 babesiosis trial patient ahead of schedule, supporting possible early interim analysis.
May 15, 2026
earnings
60 Degrees Pharmaceuticals Announces First Quarter 2026 Results
60 Degrees Pharmaceuticals Announces First Quarter 2026 Results
Apr 17, 2026
Clinical Trial
Long-Term Safety Study of Tafenoquine
Phase Phase 2 — COMPLETED
Apr 15, 2026
other
60 Degrees Pharma Announces ARAKODA (tafenoquine) for Malaria Prevention is Now Available on Runway Health Travel Website
ARAKODA® now available via Runway Health, enabling U.S. travelers to access once-weekly malaria prevention through a convenient telehealth platform.
Mar 31, 2026
earnings
60 Degrees Pharmaceuticals Announces 2025 Annual Results
60 Degrees Pharma (Nasdaq: SXTP) FY25 revenue +65% to $1.0M; improved net loss; continued clinical, commercial, and partnership momentum.
Mar 18, 2026
regulatory
60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract
60 Degrees files NDIN with FDA for Australian Chestnut Extract; May 25 decision deadline. FSU capsule license option expands commercialization strateg
Mar 12, 2026
short_interest
FTD: SXTP — 510,466 shares ($1.6M) failed to deliver
Settlement: 20260312, Price: $3.22, FTD Value: $1,643,700.52, 60 DEGREES PHARMACEUTICALS INC
Mar 11, 2026
other
60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial
All three patients in 60 Degrees Pharma’s expanded access study were cured of relapsing babesiosis after tafenoquine treatment, supporting guideline r